603367 辰欣药业
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,739,773-15.97%3,981,5724,462,3494,066,0883,782,593
减:营业总成本1,493,370-17.06%3,483,4633,866,6833,717,6183,536,814
    其中:营业成本762,687-12.82%1,729,0941,839,0241,789,2931,684,647
               财务费用(12,036)-29.96%(32,483)(33,671)(27,876)(9,084)
               资产减值损失(44,149)16.87%(56,026)(73,497)(16,462)(21,297)
公允价值变动收益20,860147.59%10,528(10,375)(3,120)(6,090)
投资收益34,66589.31%62,30444,11818,68072,513
    其中:对联营企业和合营企业的投资收益1411,434.98%(484)132(753)4,166
营业利润256,735-11.51%572,048592,578364,583334,421
利润总额256,450-12.19%575,773595,857366,191336,132
减:所得税费用25,16237.15%60,83370,43013,9202,230
净利润231,288-15.50%514,940525,426352,271333,902
减:非控股权益2,137-37.13%6,0344,0882,313(245)
股东净利润229,151-15.23%508,906521,338349,959334,146

市场价值指针
每股收益 (元) *0.510-15.00%1.1201.1500.7700.740
每股派息 (元) *0.188-14.55%0.4400.4360.3350.300
每股净资产 (元) *13.4404.79%13.14112.64911.76311.150
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容